Key points are not available for this paper at this time.
Answers are grounded in this paper and cite their sources.
May support pentavalent WC3 reassortant vaccine for severe rotavirus prevention; leaves open long-term impact in diverse settings.
From Sanofi Pasteur and the Department of Pediatrics, University of Pennsylvania, Doylestown, PA. Accepted for publication March 8, 2006. Dr. Plotkin is coholder of a patent for the WC-3 rotavirus strain and its reassortants. Address for correspondence: Stanley A. Plotkin, MD, Emeritus Professor of Pediatrics, University of Pennsylvania, 4650 Wismer Road, Doylestown, PA 18901; E-mail: [email protected].
No takes yet. Share an insight, caveat, or question.
Stanley A. Plotkin (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: